The US Food and Drug Administration (FDA) has issued a warning letter to pharmaceutical firm Glenmark for "significant violations of Current Good Manufacturing Practice regulations" at its Goa plant. FDA said the plant administration failed to establish and follow required laboratory control mechanisms. The letter also pointed out Glenmark's failure to probe discrepancies in its finished products.